Smoking as a Permissive Factor of Periodontal Disease in Psoriasis

Márk Antal1,*, Gábor Braunitzer2,*, Nikos Mattheos3, Rolland Gyulai4, Katalin Nagy2

1 University of Szeged, Faculty of Dentistry, Department of Operative and Esthetic Dentistry, Szeged, Hungary, 2 University of Szeged, Faculty of Dentistry, Department of Oral Surgery, Szeged, Hungary, 3 The University of Hong Kong, Faculty of Dentistry, Department of Oral Rehabilitation, Hong Kong, SAR PR China, 4 University of Szeged, Faculty of Medicine, Department of Dermatology and Allergology, Szeged, Hungary and University of Pécs, Department of Dermatology, Venerology and Oncodermatology, Pécs, Hungary

Abstract

Background: Population-based studies have identified smoking as a pathogenetic factor in chronic periodontitis. At the same time, chronic periodontal disease has also been found to occur more often in persons suffering from psoriasis than in controls with no psoriasis. It is known that smoking aggravates both periodontal disease and psoriasis, but so far it has not been investigated how smoking influences the occurrence and severity of periodontal disease in psoriasis.

Methods: A hospital-based study was conducted to investigate this question. The study population consisted of 82 psoriasis patients and 89 controls. All patients received a full-mouth periodontal examination, and a published classification based on bleeding on probing, clinical attachment level and probing depth was utilized for staging. Both patients and controls were divided into smoker and non-smoker groups, and the resulting groups were compared in terms of periodontal status. Beyond the descriptive statistics, odds ratios were computed.

Results: Psoriasis in itself increased the likelihood of severe periodontal disease to 4.373 (OR, as compared to non-smoker controls, p<0.05), while smoking increased it to 24.278 (OR, as compared to non-smoker controls, p<0.001) in the studied population. In other words, the risk of severe periodontal disease in psoriasis turned out to be six times higher in smokers than in non-smokers.

Conclusions: The results of this study corroborate those of other studies regarding the link between psoriasis and periodontal disease, but they also seem to reveal a powerful detrimental effect of smoking on the periodontal health of psoriasis patients, whereby the authors propose that smoking may have a permissive effect on the development of severe periodontal disease in psoriasis.

Introduction

Several chronic illnesses can be traced back to alcohol consumption, sedentary lifestyle, unhealthy nutrition or smoking. Smoking, in particular, is a global public health problem [1]. Population-based epidemiological studies have found that periodontal disease is more common in smokers than in nonsmokers [2,3]. Beyond the obvious explanation that tobacco smoke is a local irritant, it has been shown that smoking favors colonization by specific periodontopathic bacteria [4], modulates cellular immunity [5–7] and favors the development and aggravation of autoimmune and immune-mediated conditions [8,9], including psoriasis [10]. Smoking, therefore, appears to be a risk factor for both periodontal disease and psoriasis. What is more interesting is that psoriasis and periodontal disease seem to be associated themselves. It was Yamada and colleagues in 1992 who first reported a case of psoriasis in which exacerbation of the cutaneous disease was accompanied by gingival epithelial changes and periodontal bursts [11], but the first blinded, case-controlled study on the assumed association was published only eighteen years later by Preus and colleagues [12]. This was the first study to seriously raise the issue of the possible association between the two conditions, followed by the studies of Lazaridou et al. [13] and Keller and Lin [14], both of which corroborated the findings of the Preus group.

It is established that the immunopathogenesis of psoriasis [15] and the aggravation of periodontal disease [16] is linked to altered T-lymphocyte-mediated immunity. Periodontal disease turns progressive when B-cell/plasma cell responses become dominant in the periodontal inflammatory process, which is preceded by the oligoclonal expansion of Th2 lymphocytes. These lymphocytes stimulate B-cells and induce humoral immune responses by secreting interleukins IL-4, IL-5 and IL-10 (see Table 1). It is to be noted that Th1 cells are also capable of stimulating B cells by secreting INF-γ. This can be an alternative way of shifting the...
immune response toward B cell dominance, especially in the context of suppressed T cell responses (as it happens in the oligoclonal expansion of Th2 cells). Th1 cells are stimulated by IL-6, IL-8, IL-12, IL-18, TNF-α and INF-γ, the levels of all of which were found to be elevated in the serum of patients with chronic plaque psoriasis [17]. It might not be too far-fetched to hypothesize that psoriasis can aggravate periodontal disease because enhanced Th1 INF-γ secretion furthers the effects of Th2 dominance. However, the elaborate examination of the connection between periodontal disease and psoriasis is no subject of this study.

As tobacco smoking also interferes with immunity, favors colonization by periodontopathic bacteria and acts as a local irritant, we hypothesized that smoking may act as a trigger or permissive factor of periodontal disease in patients suffering from psoriasis. To test this hypothesis, the prevalence and severity of periodontal disease was assessed in a group smoking and non-smoking psoriasis patients and a group of smoking and non-smoking psoriasis-free controls. The specific question we sought an answer to was whether periodontal disease occurs more often and in a more serious form in smoking psoriasis patients than in non-smoking psoriasis patients. The primary aim of the study, therefore, was to find evidence for or against the hypothesized permissive role of smoking.

Methods

Ethics statement

The study was approved by the Human Ethics Review Board of the University of Szeged (approval Nos. 2848 and 2879), and the study design conformed to the Declaration of Helsinki in all respects. Written informed consent was obtained from all participants.

Protocol and Study Participants

A hospital-based case-control study was conducted in 2012. Participants (n = 82) were selected from the patients of the Psoriasis Outpatient Unit of the Department of Dermatology and Allergology, University of Szeged. The control group (n = 89) was recruited from people attending mandatory lung screening in the same city and the same period, on a voluntary basis. Controls were age-matched to patients, but the sex ratios were also almost identical (see Table 2.). Required sample size was calculated with G*Power 3.1.5. (University of Kiel, Germany), a software designed especially for statistical power and sample size computation [18]. The software allows the computation of achieved statistical power (post-hoc) and required sample size (a priori). As mostly categorical variables were to be analyzed, a priori sample size estimation was performed for crosstabs/chi square/contingency tables, with the following input parameters: effect size (w): 0.3; α: 0.05; power (1-β): 0.85; DF: 3. Required sample size turned out to be n = 50, but much more cases were available, whereby, also expecting dropout, it was decided that 100 cases and 100 controls would be examined. This way, even with the dropout of 18 cases and 11 controls, a statistical power over 0.9 was achieved.

Patients were eligible for the study if they were diagnosed with psoriasis (defined as ICD-10 L40.0-L40.9) by a dermatologist. The diagnosis of psoriasis was set up earlier than the beginning of this study in all cases, whereby dermatological examination was not regarded as a direct part of this study, neither was it listed on the informed consent forms as such. Exclusion criteria for both groups were determined based on the literature of the subject and included obesity (BMI ≥30), excessive alcohol consumption, drug abuse, diabetes mellitus, oestrogen deficiency, diseases causing neutropenia and local or systemic inflammatory conditions (other than psoriasis) [19,20]. Dropout resulted partially from meeting one or more of the exclusion criteria (especially excessive self-reported alcohol consumption), but there were subjects who quit by their own will before the intraoral examination, and a number of subjects failed to provide tobacco use data. Demographic and tobacco use data were collected by a questionnaire. Medical information on both controls and psoriasis patients was extracted from patient files and hospital records. Participants were divided into smoker and non-smoker groups.

Table 1. The applied clinical staging and the corresponding pathological/pathophysiological changes.

| CLINICAL STAGING (Fernandes et al., 2009) | PATHOLOGY/PATHOPHYSIOLOGY (Ohlrich et al., 2009) |
|------------------------------------------|--------------------------------------------------|
| 1. NO CLINICAL SIGNS - no clinical attachment loss (CAL) or bleeding on probing (BOP) | NO LESION - NOT CLASSIFIED EXPLICITLY IN OHLRICH ET AL. |
| GINGVITIS-NOT CLASSIFIED EXPLICITLY IN FERNANDES ET AL.) (CPITN 1) | 1. INITIAL LESION - up to 4 days following plaque accumulation. Polymorphonuclear leukocytes (PMN), complement activation, loss of connective tissue. Mast cells release tumor necrosis factor alpha, PMNs migrate into the gingival sulcus, but as the bacteria are protected by the biofilm, abortive phagocytosis occurs. PMNs release lysosomal contents, which leads to further tissue destruction. |
| 2. EARLY PERIODONTITIS - CAL ≤1 mm in ≥2 teeth (CPITN 2) | 2. EARLY/STABLE LESION - 7-21 days after plaque accumulation, clinically evident from day 12. Dominantly macrophages and lymphocytes (CD4+CD8+ 2:1). Perivascular inflammatory infiltrate. Intercellular spaces between epithelial cells widen, bacterial products infiltrate the gingival tissues at a higher rate. Escalation of response. If plaque removed, tissue remodeling can take place. |
| 3. MODERATE PERIODONTITIS - 3 sites with CAL ≥4 mm and at least 2 sites with probing depth (PD) ≥3 mm (CPITN 3) | 3. ESTABLISHED OR PROGRESSIVE LESION - dominantly a B cell/plasma cell response. High levels of IL-1 and IL-6: connective tissue loss, breakdown of bone. |
| 4. SEVERE PERIODONTITIS - CAL ≥6 mm in ≥2 teeth and PD ≥5 mm in ≥1 site (CPITN 4) | 4. ADVANCED LESION - Overt loss of attachment. High levels of IL-1, TNF-α and PGE2 stimulate fibroblasts and macrophages to produce matrix metalloproteinases. The junctional epithelium progresses in apical direction (deepening periodontal pocket). Oligoclonal Th1, (CD4+) dominance. |

The approximate CPITN stage is also given (in brackets). doi:10.1371/journal.pone.0092333.t001

PLOS ONE | www.plosone.org 2 March 2014 | Volume 9 | Issue 3 | e92333
Table 2. Descriptive statistics of the study and control groups with the characteristics of the subsamples.

|                          | PSORIASIS | CONTROL |
|--------------------------|-----------|---------|
| Age (mean±SD, years)     | 50.9±13.4 | 50.3±13.7 |
| smoker subsample         | 48.5±14.0 | 43.3±12.4 |
| nonsmoker subsample      | 54.7±12.9 | 52.9±14.7 |
| Sex ratio F:M (n(%)|n(%)|)   | 45(55%):37(45%) | 44(49%):45(51%) |
| smoker subsample         | 24(60%):21(40%) | 12(50%):12(50%) |
| nonsmoker subsample      | 23(49%):24(51%) | 33(51%):32(49%) |
| Smoking (n(%)            | 35(43%)   | 24(27%) |
| Periodontal status in smokers (n) | healthy: - | reference category | healthy: 10 |
|                          | early: 5 | p<0.001 | early: 8 |
|                          | moderate: 13 | p<0.001 | moderate: 4 |
|                          | severe: 17 | n.s. | severe: 2 |
| Periodontal status in nonsmokers (n) | healthy: 10 | reference category | healthy: 25 |
|                          | early: 13 | n.s. | early: 19 |
|                          | moderate: 18 | p = 0.05 | moderate: 17 |
|                          | severe: 6 | p<0.005 | severe: 4 |

To keep the table transparent, percentages have been rounded to whole numbers. Note that no periodontally healthy smoker psoriasis patients were found. A trend analysis ($\chi^2$ with adjusted residuals) revealed a significant trend ($\chi^2 = 48.074$, $p = 0.000$), with non-smoker controls being the less likely to have any stage of periodontal disease and smoker patients being the most likely to have the severe stage. Significance values refer to the comparison of odds with healthy as the reference category (see also Table 3).

doi:10.1371/journal.pone.0092333.t002

based on their self-reported current tobacco use. To minimize desirable response tendency in this crucial aspect, smoking was not pointed out to the participants as the target variable until all study procedures had been finished.

The clinical staging of periodontal disease is still a matter of debate, even though the progression of the disease is well established in pathological terms [16]. The most widely used classification is the Community Periodontal Index of the WHO (CPITN) [21]. Applicable as it may be for clinical purposes, CPITN defines rather wide categories, which carries the risk of oversampling. Therefore we decided to use the more detailed (and thus more strict) staging proposed by Fernandes and colleagues [22]. The staging requires the following parameters to be recorded: the number of missing teeth (excluding third molars), Plaque Index (PI; also known as the Silness-Loe Index), bleeding on probing (BOP; the presence or absence of bleeding within 15 sec after probing), probing depth (PD; in millimeters), and clinical attachment level (CAL; to describe the position of the soft tissue in relation to the cemento-enamel junction).

Clinical Examination

In order to record the above mentioned parameters, all patients received a full mouth periodontal examination, performed by a periodontist. BOP, PD and CAL were examined six sites per tooth (mesio-buccal, buccal, disto-buccal, disto-lingual, lingual, mesio-lingual), with the exception of third molars. Williams probes (Hu-Friedy Manufacturing Co., Chicago, USA) were used. Table 1 shows the categories of the applied staging and the corresponding pathological/pathophysiological status.

Statistical Analysis

The study and control groups were compared by smoking status. To express the probability that a member of a given group develops a given clinical degree of periodontal disease, multinomial logistic regression was conducted and the odds ratios were calculated. In the multinomial model, disease severity (healthy, early, moderate, severe) was defined as the outcome variable, smoking status (smoker or non-smoker), and group (psoriasis or control) were defined as factors, and smoking intensity (expressed as the number of cigarettes smoked per day) was defined as a covariate. Descriptive statistics and odds ratios were calculated in SPSS 17.0 (SPSS, Inc., Chicago, USA).

Results

The population

Table 2. shows the descriptive statistics of both the study and the control groups. Females were slightly over-represented in the psoriasis group (n_females = 45, n_males = 37) while in the control group the sexes were represented almost perfectly equally (n_females = 44, n_males = 45). Crosstab analysis with $\chi^2$ test was conducted to find out if sex was significantly associated with disease severity, but the association turned out to be non-significant for both patients ($\chi^2 = 5.184$, $p = 0.05$) and controls ($\chi^2 = 5.029$, $p = 0.387$), whereby sex was not included in the multinomial regression. Patients and controls were age-matched (mean age for the entire sample: 50.6 years). The division into four groups by diagnosis (psoriasis or control) and smoking status (yes or no) for the purposes of the analysis did not change these parameters significantly, that is, the ratios remained representative of the whole sample. Group membership (i.e. patient or control) was shown to be significantly associated with disease severity ($\chi^2 = 27.337$, $p = 0.000$).

In the psoriasis group 35 persons defined themselves as smoker (43%). The number of smokers was lower among the control group, only 24 persons defined themselves as smoker (27%). In the psoriasis-smoker group no patient could be categorized as periodontally healthy. 14% of this group had early, 37% moderate and 49% severe periodontal disease. Among non-smoker patients 21% were classified as healthy, 28% as having early, 39% as having moderate and 12% as having severe periodontal disease. 42% of smoking controls was periodontally healthy, 33% had
early, 17% moderate and 8% severe periodontal disease. Nonsmoking controls were periodontally healthy in 38%, 29% had early periodontal disease, while in 26% of the cases the disease presented in its moderate and in 7% in its severe form. These data reflect opposing tendencies between smoker patients and non-smoker controls, that is, while in the smoker patient subsample the severe stage of periodontal disease is the most frequent, and no periodontally healthy patient is seen, in the non-smoker control subsample exactly the opposite can be observed (Figure 1.).

Smoking history and smoking intensity

In terms of smoking history (expressed in years) and their intensity of smoking (expressed as the number of cigarettes smoked per day), controls and psoriasis patients turned out to be quite similar. Smoking controls had smoked for a mean of 20.9 years (mode: 20 years, SD: 11.97), and they smoked a mean of 16 cigarettes a day (mode: 20 cigarettes, SD: 11.67). Smoking patients had smoked for an average of 16.57 years (mode: 20 years, SD: 12.37), and they smoked an average of 15 cigarettes a day (mode: 20 cigarettes, SD: 8.57). Indeed, the two groups exhibited no statistically significant difference in either of these parameters (MWU = 315, n1 = 35, n2 = 24, p = 0.17, years; MWU = 758, n1 = 35, n2 = 24, p = 0.57, cigarettes). The crosstab analysis revealed that smoking status in itself was significantly associated with disease severity only in patients (\( \chi^2 = 18.258, p = 0.000 \)). In controls, no significant association was seen (\( \chi^2 = 0.935, p = 0.612 \)). However, when the data were re-coded so that the outcome variable was not disease severity, but the occurrence of any stage of the disease, the association was highly significant (\( \chi^2 = 89.000, p = 0.000 \)).

Odds Ratios

Odds ratios with significance and confidence intervals are given in Table 3. Odds ratios were calculated in a multinomial logistic regression model. Smokers and controls were compared stagewise, according to the applied classification. The factors of the model were smoking status (smoker or non-smoker) and group (patient or control), and the covariate was smoking history (in years). Five comparisons were done, that is, non-smoker controls were compared with smoker controls (OR\(_{EARLY} = 1.053, OR_{MODERATE} = 0.588, OR_{SEVERE} = 1.250 \)), with non-smoker patients (OR\(_{EARLY} = 1.944, OR_{MODERATE} = 2.647, OR_{SEVERE} = 4.373 \)) and with smoker patients (OR\(_{EARLY} = 1.711, OR_{MODERATE} = 2.500, OR_{SEVERE} = 24.278 \)), smoker patients were also compared with non-smoker patients (OR\(_{EARLY} = 6.082, OR_{MODERATE} = 1.712, OR_{SEVERE} = 4.480 \)), and smoker controls were compared with smoker patients (OR\(_{EARLY} = 1.904, OR_{MODERATE} = 9.900, OR_{SEVERE} = 2.589 \)). Significantly higher odds of developing moderate (\( p = 0.05 \)) and severe (\( p < 0.05 \)) periodontal disease were found when non-smoker patients were compared against non-smoker controls (the periodontal risk of psoriasis alone). The highest odds ratio resulted from the comparison of smoker patients with non-smoker controls (24.278, \( p < 0.001 \)), which is 4.43 times higher than the combination of the individual odds of smoking (1.250, n.s.) and psoriasis (4.373, \( p < 0.05 \)). It must be noted, though, that the high odds ratio had a rather wide confidence interval. When compared with non-smoker patients, smoker patients’ odds of developing periodontal disease was significantly higher at all three stages (\( p < 0.001 \)). Finally, as compared to smoker controls, smoker patients’ odds of developing early or moderate periodontal disease were also significantly higher (\( p < 0.001 \), but no significant difference was observed regarding the severe stage of the disease.

The covariate smoking history was significantly associated with disease severity in both patients (\( \chi^2 = 12.204, p = 0.014 \)) and controls (\( \chi^2 = 9.869, p = 0.02 \)). The odds ratios were positive for the moderate and severe stages in both groups (OR\(_{CONTROL, MODERATE} = 1.145, CI: 0.999–1.312; OR_{CONTROL, SEVERE} = 1.164, CI: 0.963–1.408; OR_{PATIENT, MODERATE} = 1.112, CI: 0.939–1.318; OR_{PATIENT, SEVERE} = 1.185, CI: 0.998–1.406), indicating that a longer smoking history significantly increases the odds that the moderate or severe stage of the disease occurs, as compared to the early stage.
acts as a permissive factor.

1.2, indicating a synergistic effect. It seems, therefore, that smoking
value of the synergy factor for the odds of psoriasis and smoking is
(antagonism) and SF
combined odds of the examined factors. SF = 1 expresses the
logOR2
calculated as

observed in smoker patients is not simply the odds of psoriasis and
non-smoker controls), while smoking appears to increase this to
24.278. From this it may be conferred that what is
observed 24.278. In other words, the risk of severe periodontal disease in
patients who do not smoke. Psoriasis in itself increases the
likelihood of severe periodontal disease to 4.373 (as compared to
non-smoker controls), while smoking appears to increase this to
24.278. In other words, the risk of severe periodontal disease in
psoriasis is approximately six times higher in smokers than in
non-smokers. It would be reasonable to infer that this increase in risk is
merely the result of the individual risk factors adding up. To test
that possibility, odds ratios were combined and the synergy factor
was calculated.

Combined odds expresses the probability of a given condition if
all combined risk factors are present. For samples of similar size,
combination of odds is done by averaging their logs (\( \log OR_1/\log OR_2 \)). For psoriasis alone (4.373) and smoking alone (1.250), the
combined odds of severe periodontal disease is 6.60, far below the
observed 24.278. From this it may be conferred that what is
observed in smoker patients is not simply the odds of psoriasis and
smoking added up. Computation of the synergy factor corroborates
this suspicion. The synergy factor was devised by Borja and
coworkers [23] to allow the estimation of whether two factors are
in a positive or negative interaction in terms of bringing about a
given condition, based on their individual odds. The factor is
calculated as \( SF = OR_{12}/(OR_1 \times OR_2) \), where \( OR_{12} \) expresses
the combined odds of the examined factors. SF = 1 expresses
the simple addition of the odds, SF<1 expresses negative interaction
(antagonism) and SF>1 expresses positive interaction (synergy). The
value of the synergy factor for the odds of psoriasis and smoking is
1.2, indicating a synergistic effect. It seems, therefore, that smoking
acts as a permissive factor.

It was also found that the association between smoking status
and disease severity is significant only in the patient group, which
is also to support that exposure to cigarette smoke and psoriasis act
together toward the aggravation of periodontal disease. The lack
of significant association, however, should not be interpreted as
evidence that cigarette smoke alone does not cause periodontal
disease. Evidence suggests that it does [24], and the additional
analysis also showed that when the target variable is the
occurrence of periodontal disease, the association is highly
significant. From this it might be inferred, that smoking increases
the odds of periodontal disease in both controls and psoriasis
patients, but psoriasis patients are predisposed to the more severe
forms of the disease.

A further interesting result is the significant association of
smoking history with the occurrence of the moderate and severe
forms of periodontal disease in both groups. Together with the
lack of significant association with the number of cigarettes
smoked per day, it suggests that the key factor in the proposed
permissive role of cigarette smoke is chronic exposure, apparently
regardless of how heavy a smoker one is.

As no study before has dealt with the effects of smoking on
periodontal disease severity in psoriasis, it is beyond our limitations
to give an exact explanation of these findings. However, enough is
known about the pathogenesis of psoriasis and periodontal disease
and the pathophysiological effects of smoking to allow the
articulation of the elements of a hypothesis, which we briefly
delineate here.

As pointed out by Ohlrich and co-workers, the most readily
observable difference between the early and later stages of
periodontal disease is that in the later stages the inflammatory
response is dominated by B lymphocytes, instead of T lymphocytes
[16]. It is in the context of this exaggerated and maladaptive B
cell/plasma cell response that periodontal tissue destruction and

| Table 3. Odds ratios by clinical staging. |
|-----------------------------------------|
| COMPARISON                  | STAGE | OR  | Sig. | 95% CI (lower;upper) |
|-----------------------------|-------|-----|------|----------------------|
| SMOKER CONTROLS (vs. non-    | early | 1.053 | n.s. | 0.394;3.177 |
| smoker controls)            |       |     |      |                      |
|                             | moderate | 0.588 | n.s. | 0.158;2.187 |
|                             | severe | 1.250 | n.s. | 0.197;7.942 |
| NON-SMOKER PATIENTS (vs.    | early | 1.944 | n.s. | 0.706;5.353 |
| non-smoker controls)        |       |     |      |                      |
|                             | moderate | 2.647 | p = 0.05 | 0.985;7.113 |
|                             | severe | 4.373 | p < 0.05 | 1.114;17.169 |
| SMOKER PATIENTS (vs. non-   | early | 1.711 | n.s. | 0.618;4.732 |
| smoker controls)            |       |     |      |                      |
|                             | moderate | 2.500 | n.s. | 0.924;6.761 |
|                             | severe | 24.278 | p < 0.001 | 5.207;113.189 |
| SMOKER PATIENTS (vs. non-   | early | 6.082 | p < 0.001 | 1.516;2.440 |
| smoker patients)            |       |     |      |                      |
|                             | moderate | 1.722 | p < 0.001 | 3.353;5.689 |
|                             | severe | 4.480 | p < 0.001 | 1.651;6.851 |
| SMOKER PATIENTS (vs. smoker | early | 1.904 | p < 0.001 | 1.202;3.016 |
| controls)                   |       |     |      |                      |
|                             | moderate | 9.900 | p < 0.001 | 1.568;6.262 |
|                             | severe | 2.589 | n.s. | 2.108;2.695 |

In each case, the ratios express the odds that a member of the given category (printed in capitals) develops the given stage of periodontitis in comparison with the members of another category (in brackets). Significance levels and 95% confidence intervals (with lower and upper limits) are also given.

doi:10.1371/journal.pone.0092333.t003

Discussion

In the present study it was demonstrated that psoriasis patients
who smoke are at an approximately sixfold higher risk of
developing severe periodontal disease, as compared to psoriasis
patients who do not smoke. Psoriasis in itself increases the
likelihood of severe periodontal disease to 4.373 (as compared to
non-smoker controls), while smoking appears to increase this to
24.278. In other words, the risk of severe periodontal disease in
psoriasis is approximately six times higher in smokers than in
non-smokers. It would be reasonable to infer that this increase in risk is
merely the result of the individual risk factors adding up. To test
that possibility, odds ratios were combined and the synergy factor
was calculated.
bone breakdown occurs. Our proposed hypothesis, therefore, centers around this T-to-B shift, which appears to be the key event in the aggravation of periodontal disease, and how cigarette smoke might play a permissive role in the process. Here we concentrate only on a putative immunological background, while we understand that additional factors, like the detrimental effect of smoking on gingival circulation [23,26] can also contribute to the end result.

It is well established that psoriasis is associated with a milieu of inflammatory mediators that favors a shift toward B cell responses. Serum levels of the inflammatory mediators IL-6, IL-8, IL-12, IL-18, TNF-α and INF-γ were found to be elevated in plaque psoriasis [17]. These mediators are all documented to activate B cells [27–30]. TNF-α is also a potent stimulant of fibroblasts and macrophages, which, upon activation, release matrix metalloproteases [16]. As mentioned before, periodontal disease itself is associated with Th₂ expansion. This, on one hand, suppresses T cell responses, but Th₂ cells, in the presence of antigen, can stimulate B cells too [31]. Therefore, it might be argued that psoriasis increases susceptibility to destructive immune responses in general by shifting the immune response profile toward B cell responses, which would explain the original observation - also corroborated by this study- that patients with psoriasis develop periodontal disease more often than psoriasis-free individuals.

How, then, might cigarette smoke boost this effect? We propose that toll-like receptor 4 (TLR 4) can play a key role here. Toll-like receptors are preferentially expressed on immune cells, and mediate immune responses. TLR4 on the surface of Th₁ cells activate these cells upon binding to bacterial lipopolysaccharides to secrete INF-γ, a potent B cell activator [32]. Normally, this is part of the immune response to bacterial colonization of the gingival sulcus. However, if TLR 4 is overexpressed, the response may become exaggerated and maladaptive. Pace and co-workers demonstrated that cigarette smoke causes upregulation of TLR4 in airway epithelial cells of smokers with COPD, and they proposed that this upregulation might be the reason why a dominantly Th₁-regulated immune response is seen in the airways of COPD patients [33]. The authors also demonstrated that cigarette smoke increased epithelial cells’ ability to bind bacterial lipopolysaccharides [33]. TLR4 upregulation was demonstrated in the psoriatic skin too [34]. It is not known if cigarette smoke has the same effect in the periodontal tissues (and on the surface of Th₁ cells), but it seems plausible to assume that TLR 4 upregulation can be the key step in the destructive T- to B- shift in periodontal disease in the context of an already B-biased inflammatory mediator environment. Based on the literature, we propose that the examination of the effects of cigarette smoke on TLR4 expression in the gingival tissues could be a logical next step toward the understanding of our observations.

Conclusions

The results of this study corroborate those of other studies regarding the link between psoriasis and periodontal disease, but they also seem to reveal a powerful detrimental effect of smoking on the periodontal health of psoriasis patients, whereby we propose that smoking might have a permissive effect on the development of severe periodontal disease in psoriasis. It seems plausible to propose that smoking exerts this effect through the upregulation of TLR-4, but this cannot be decided without further research, as at the moment no data are available regarding the periodontium.

Acknowledgments

The authors thank Dr. Annamária Kertész, for her continued support, expertise and help during the research. The authors would like to express their acknowledgment and honour to Dr. György Benedek for his guidance and mentoring.

Author Contributions

Conceived and designed the experiments: MA GB KN NM. Performed the experiments: MA RG. Analyzed the data: GB. Wrote the paper: MA GB KN NM RG.

References

1. Edwards R (2004) The problem of tobacco smoking. BMJ 328: 217–219.
2. Beck JD, Koch GG, Rozier RG, Tudor GE (1990). Prevalence and risk indicators for periodontal attachment loss in a population of older community-dwelling blacks and whites. J Periodontal 61: 521–528.
3. Tomar SL, Auma S (2000) Smoking-attributable periodontitis in the United States: findings from NHANES III. National Health and Nutrition Examination Survey. J Periodontal 71: 743–751.
4. Kubota M, Tamano-Nakanishi M, Yamada S, Okuda K, Ishihara K (2011) Effect of smoking on subgingival microflora of patients with periodontitis in Japan. BMC Oral Health 11: 1.
5. Korn S, Wiewrodt R, Walz YC, Becker K, Mayer E, et al. (2005) Characterization of the interstitial lung and peripheral blood T cell receptor repertoire in cigarette smokers. Am J Respir Cell Mol Biol 32: 142–148.
6. Sopori M (2002) Effects of cigarette smoke on the immune system. Nat Rev Immunol 2: 372–377.
7. Sullivan AK, Simonian PL, Falta MT, Mitchell JD, Cogrove GP, et al. (2005) Oligoclonal CD4⁺ T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med 172: 590–596.
8. Masdottir B, Jonsson T, Manfredsdottir V, Vikingsson A, Brekkan A, et al. (2007) Gingival blood flow measurements and gingival crevicular fluid in smokers and non-smokers. J Periodontol 78: 1774–1782.
9. Mathews JD, Whittingham S, Hooper BM, Mackay IR, Stenhouse NS (1973) Smoking and gum disease. J Periodontol 44: 429–434.
10. Mathews JD, Whittingham S, Hooper BM, Mackay IR, Stenhouse NS (1973) The problem of tobacco smoking. BMJ 328: 217–219.
11. Mathews JD, Whittingham S, Hooper BM, Mackay IR, Stenhouse NS (1973) Smoking and gum disease. J Periodontol 44: 429–434.
12. Mathews JD, Whittingham S, Hooper BM, Mackay IR, Stenhouse NS (1973) Smoking and gum disease. J Periodontol 44: 429–434.
13. Mathews JD, Whittingham S, Hooper BM, Mackay IR, Stenhouse NS (1973) Smoking and gum disease. J Periodontol 44: 429–434.
14. Mathews JD, Whittingham S, Hooper BM, Mackay IR, Stenhouse NS (1973) Smoking and gum disease. J Periodontol 44: 429–434.
27. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, et al. (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73–76.

28. Falkoff RJ, Muraguchi A, Hong JX, Butler JL, Dinarello CA, et al. (1983) The effects of interleukin 1 on human B cell activation and proliferation. J Immunol 131: 801–805.

29. Durali D, de Goer de Herve MG, Giron-Michel J, Azzarone B, Delfraissy JF, et al. (2003) In human B cells, IL-12 triggers a cascade of molecular events similar to Th1 commitment. Blood 102: 4084–4089.

30. Rieckmann P, D’Alessandro F, Nordan RP, Fauci AS, Kehrl JH (1991) IL-6 and tumor necrosis factor-alpha. Autocrine and paracrine cytokines involved in B cell function. J Immunol 146: 3462–3468.

31. Del Prete G (1998) The concept of type-1 and type-2 helper T cells and their cytokines in humans. Int Rev Immunol 16: 427–455.

32. Netea MG, Van der Meer JW, Stuttmuller RP, Adema GJ, Kullberg BJ (2005) From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias. Antimicrob Agents Chemother 49: 3991–3996.

33. Pace E, Ferraro M, Sirna L, Meli M, Montalbano AM, et al. (2008) Cigarette smoke increases Toll-like receptor 4 and modifies lipopolysaccharide-mediated responses in airway epithelial cells. Immunology 124: 401–411.

34. Curry JL, Qin JZ, Bonish B, Carrick R, Bacon P, et al. (2003) Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 127: 178–186.